Mohammed Safeer V S , Palak Gupta , Simran Behl , Dipika Bansal , Jitendra Kumar Sahu
{"title":"印度应用程序商店中的癫痫移动医疗应用程序：使用移动应用程序评分量表进行系统回顾和内容分析","authors":"Mohammed Safeer V S , Palak Gupta , Simran Behl , Dipika Bansal , Jitendra Kumar Sahu","doi":"10.1016/j.eplepsyres.2024.107331","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>The growing prevalence of smartphones may prompt individuals with epilepsy to pursue unfulfilled healthcare requirements through mobile health (mHealth) apps, but the content and quality of these mHealth apps are rarely analysed. Hence, this study aimed to identify and assess the quality of epilepsy apps for patients with epilepsy (PWE), their caregivers, and healthcare practitioners (HCPs) available in the Play Store and App Store of India.</p></div><div><h3>Methods</h3><p>We performed a systematic search on the Google Play Store and Apple App Store of India to identify the mHealth apps for epilepsy which were released and updated till May 2023. The identified applications were downloaded and the quality was assessed using a Mobile app rating scale (MARS) for the overall quality, Aesthetics, Engagement, Functionality, and Information by three independent reviewers. The intraclass correlation coefficient (ICC) was calculated to assess the interrater reliability between the reviewers. An unpaired t-test was calculated to analyse the difference in mean scores for Android and iOS applications.</p></div><div><h3>Results</h3><p>The systematic search yielded a total of 2518 apps, out of which 26 were selected for inclusion in the study. Among these, 9 apps were compatible with Android, 11 with iOS, and 6 on both platforms. The mean (SD) MARS score of the apps was 3.5 (0.6) and the ICC for the overall app quality was 0.90 (95% CI: 0.82–0.96). Overall, apps scored highest in functionality (3.9), followed by aesthetics (3.6), information (3.3), and engagement (3.2). Among the included apps, the overall quality score was found to be higher for iOS apps than Android (MD = 0.54; 95% CI: 0.02 – 1.07; p-value: 0.042).</p></div><div><h3>Conclusion</h3><p>Our study identified twenty-six mHealth applications for epilepsy that integrated various aspects of epilepsy self-management. The results of this study emphasize the importance of ensuring that current and future applications offer evidence-based information, integrate features that align with patient preferences, and generate evidence regarding the effectiveness of application usage.</p></div>","PeriodicalId":11914,"journal":{"name":"Epilepsy Research","volume":"201 ","pages":"Article 107331"},"PeriodicalIF":2.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Mobile health applications for epilepsy in Indian app stores: A systematic review and content analysis using the mobile app rating scale\",\"authors\":\"Mohammed Safeer V S , Palak Gupta , Simran Behl , Dipika Bansal , Jitendra Kumar Sahu\",\"doi\":\"10.1016/j.eplepsyres.2024.107331\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>The growing prevalence of smartphones may prompt individuals with epilepsy to pursue unfulfilled healthcare requirements through mobile health (mHealth) apps, but the content and quality of these mHealth apps are rarely analysed. Hence, this study aimed to identify and assess the quality of epilepsy apps for patients with epilepsy (PWE), their caregivers, and healthcare practitioners (HCPs) available in the Play Store and App Store of India.</p></div><div><h3>Methods</h3><p>We performed a systematic search on the Google Play Store and Apple App Store of India to identify the mHealth apps for epilepsy which were released and updated till May 2023. The identified applications were downloaded and the quality was assessed using a Mobile app rating scale (MARS) for the overall quality, Aesthetics, Engagement, Functionality, and Information by three independent reviewers. The intraclass correlation coefficient (ICC) was calculated to assess the interrater reliability between the reviewers. An unpaired t-test was calculated to analyse the difference in mean scores for Android and iOS applications.</p></div><div><h3>Results</h3><p>The systematic search yielded a total of 2518 apps, out of which 26 were selected for inclusion in the study. Among these, 9 apps were compatible with Android, 11 with iOS, and 6 on both platforms. The mean (SD) MARS score of the apps was 3.5 (0.6) and the ICC for the overall app quality was 0.90 (95% CI: 0.82–0.96). Overall, apps scored highest in functionality (3.9), followed by aesthetics (3.6), information (3.3), and engagement (3.2). Among the included apps, the overall quality score was found to be higher for iOS apps than Android (MD = 0.54; 95% CI: 0.02 – 1.07; p-value: 0.042).</p></div><div><h3>Conclusion</h3><p>Our study identified twenty-six mHealth applications for epilepsy that integrated various aspects of epilepsy self-management. The results of this study emphasize the importance of ensuring that current and future applications offer evidence-based information, integrate features that align with patient preferences, and generate evidence regarding the effectiveness of application usage.</p></div>\",\"PeriodicalId\":11914,\"journal\":{\"name\":\"Epilepsy Research\",\"volume\":\"201 \",\"pages\":\"Article 107331\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Epilepsy Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0920121124000469\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epilepsy Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0920121124000469","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目标智能手机的日益普及可能会促使癫痫患者通过移动医疗（mHealth）应用程序来追求未得到满足的医疗保健需求，但这些移动医疗应用程序的内容和质量却很少得到分析。因此，本研究旨在为癫痫患者（PWE）、其护理人员和医疗保健从业人员（HCPs）识别和评估印度 Play Store 和 App Store 中的癫痫应用程序的质量。方法我们在印度 Google Play Store 和 Apple App Store 上进行了系统搜索，以识别截至 2023 年 5 月发布和更新的癫痫移动医疗应用程序。我们下载了已确定的应用程序，并由三位独立审查员使用移动应用程序评分表（MARS）对总体质量、美观度、参与度、功能性和信息量进行了质量评估。通过计算类内相关系数（ICC）来评估评测者之间的可靠性。计算非配对 t 检验来分析 Android 和 iOS 应用程序平均得分的差异。其中，9 个应用程序与 Android 兼容，11 个应用程序与 iOS 兼容，6 个应用程序同时与这两个平台兼容。应用程序的平均（标清）MARS 得分为 3.5（0.6），应用程序总体质量的 ICC 为 0.90（95% CI：0.82-0.96）。总体而言，应用程序的功能性得分最高（3.9），其次是美观性（3.6）、信息性（3.3）和参与性（3.2）。在纳入的应用程序中，iOS 应用程序的总体质量得分高于 Android 应用程序（MD = 0.54；95% CI：0.02 - 1.07；P 值：0.042）。这项研究的结果强调了确保当前和未来的应用程序提供循证信息、整合符合患者偏好的功能以及生成有关应用程序使用效果的证据的重要性。
Mobile health applications for epilepsy in Indian app stores: A systematic review and content analysis using the mobile app rating scale
Objective
The growing prevalence of smartphones may prompt individuals with epilepsy to pursue unfulfilled healthcare requirements through mobile health (mHealth) apps, but the content and quality of these mHealth apps are rarely analysed. Hence, this study aimed to identify and assess the quality of epilepsy apps for patients with epilepsy (PWE), their caregivers, and healthcare practitioners (HCPs) available in the Play Store and App Store of India.
Methods
We performed a systematic search on the Google Play Store and Apple App Store of India to identify the mHealth apps for epilepsy which were released and updated till May 2023. The identified applications were downloaded and the quality was assessed using a Mobile app rating scale (MARS) for the overall quality, Aesthetics, Engagement, Functionality, and Information by three independent reviewers. The intraclass correlation coefficient (ICC) was calculated to assess the interrater reliability between the reviewers. An unpaired t-test was calculated to analyse the difference in mean scores for Android and iOS applications.
Results
The systematic search yielded a total of 2518 apps, out of which 26 were selected for inclusion in the study. Among these, 9 apps were compatible with Android, 11 with iOS, and 6 on both platforms. The mean (SD) MARS score of the apps was 3.5 (0.6) and the ICC for the overall app quality was 0.90 (95% CI: 0.82–0.96). Overall, apps scored highest in functionality (3.9), followed by aesthetics (3.6), information (3.3), and engagement (3.2). Among the included apps, the overall quality score was found to be higher for iOS apps than Android (MD = 0.54; 95% CI: 0.02 – 1.07; p-value: 0.042).
Conclusion
Our study identified twenty-six mHealth applications for epilepsy that integrated various aspects of epilepsy self-management. The results of this study emphasize the importance of ensuring that current and future applications offer evidence-based information, integrate features that align with patient preferences, and generate evidence regarding the effectiveness of application usage.
期刊介绍：
Epilepsy Research provides for publication of high quality articles in both basic and clinical epilepsy research, with a special emphasis on translational research that ultimately relates to epilepsy as a human condition. The journal is intended to provide a forum for reporting the best and most rigorous epilepsy research from all disciplines ranging from biophysics and molecular biology to epidemiological and psychosocial research. As such the journal will publish original papers relevant to epilepsy from any scientific discipline and also studies of a multidisciplinary nature. Clinical and experimental research papers adopting fresh conceptual approaches to the study of epilepsy and its treatment are encouraged. The overriding criteria for publication are novelty, significant clinical or experimental relevance, and interest to a multidisciplinary audience in the broad arena of epilepsy. Review articles focused on any topic of epilepsy research will also be considered, but only if they present an exceptionally clear synthesis of current knowledge and future directions of a research area, based on a critical assessment of the available data or on hypotheses that are likely to stimulate more critical thinking and further advances in an area of epilepsy research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
